FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136304269> ?p ?o ?g. }

• W3136304269 endingPage "e0247384" @default.
• W3136304269 startingPage "e0247384" @default.
• W3136304269 abstract "Background Persistent symptoms attributed to presumed tick-bite exposure constitute an unresolved medical controversy. We evaluated whether Swedish adults who met the criteria for post-treatment Lyme disease syndrome (PTLDS) exhibited characteristics distinguishable from adults who did not, but who displayed similar symptoms and disease course after suspected previous tick-bite infection (TBI). Methods and findings During 2015–2018, 255 patients–referred to the Centre for Vector-borne Infections, Uppsala University Hospital, Sweden with symptoms lasting longer than six months–were recruited. Of this group, 224 completed the study. Each patient was examined by an infectious disease specialist and, besides a full medical history, underwent a panel of blood and cerebrospinal fluid laboratory tests including hematological, biochemical, microbiological and immunological analyses, and the RAND-36 scale to measure quality of life. For analysis purposes, patients were divided into five subgroups, of which one represented PTLDS. According to serological results indicating TBI and documented/ reported objective signs of Lyme disease, 85 (38%) patients fulfilled the criteria for PTLDS and were compared with the other 139 (62%) serologically classified patients. In the PTLDS group, erythema chronicum migrans (ECM) was documented/reported in 86% of patients, previous neuroborreliosis in 15%, and acrodermatitis chronica atroficans (ACA) in 3.5%. However, there were no significant differences regarding symptoms, laboratory results or disease course between patients with PTLDS and those without laboratory evidence of Borrelia exposition. Most reported symptoms were fatigue-related (70%), musculoskeletal (79%), neurological (82%) and neurocognitive (57%). Tick bites were recalled by 74%. The RAND-36 score was significantly below that of the general Swedish population. Signs of immunological/inflammatory reactivity with myositis antibodies were detected in 20% of patients, fibrinogen levels were moderately increased in 21% and elevated rheumatoid factor in 6%. Conclusions The PTLDS group did not differ exclusively in any respect from the other subgroups, which either lacked previously documented/reported evidence of borreliosis or even lacked detectable serological signs of exposure to Lyme disease. The results suggest that symptoms often categorized as Chronic-Lyme-Disease (CLD) in the general debate, cannot be uniquely linked to Lyme disease. However, approximately 20% of the total group of patients showed signs of autoimmunity. Further studies are needed to elucidate the underlying causes and mechanisms of PTLDS and there is reason to consider a multifactorial approach." @default.
• W3136304269 created "2021-03-29" @default.
• W3136304269 creator A5002202838 @default.
• W3136304269 creator A5003696666 @default.
• W3136304269 creator A5019640187 @default.
• W3136304269 creator A5043049715 @default.
• W3136304269 creator A5055180890 @default.
• W3136304269 creator A5058757004 @default.
• W3136304269 creator A5081400464 @default.
• W3136304269 creator A5083681911 @default.
• W3136304269 creator A5084119337 @default.
• W3136304269 date "2021-03-18" @default.
• W3136304269 modified "2023-10-17" @default.
• W3136304269 title "A comprehensive clinical and laboratory evaluation of 224 patients with persistent symptoms attributed to presumed tick-bite exposure" @default.
• W3136304269 cites W1596515083 @default.
• W3136304269 cites W1786380885 @default.
• W3136304269 cites W1909286649 @default.
• W3136304269 cites W1914817624 @default.
• W3136304269 cites W1974207924 @default.
• W3136304269 cites W1996181097 @default.
• W3136304269 cites W1999368746 @default.
• W3136304269 cites W2015695342 @default.
• W3136304269 cites W2026476527 @default.
• W3136304269 cites W2038794899 @default.
• W3136304269 cites W2046904461 @default.
• W3136304269 cites W2052516514 @default.
• W3136304269 cites W2078610240 @default.
• W3136304269 cites W2083617728 @default.
• W3136304269 cites W2100584234 @default.
• W3136304269 cites W2104695445 @default.
• W3136304269 cites W2105059113 @default.
• W3136304269 cites W2123539550 @default.
• W3136304269 cites W2125497658 @default.
• W3136304269 cites W2126353156 @default.
• W3136304269 cites W2130207729 @default.
• W3136304269 cites W2133866452 @default.
• W3136304269 cites W2152348310 @default.
• W3136304269 cites W2171858853 @default.
• W3136304269 cites W2265743533 @default.
• W3136304269 cites W2318919763 @default.
• W3136304269 cites W2321758682 @default.
• W3136304269 cites W2331747679 @default.
• W3136304269 cites W2344742956 @default.
• W3136304269 cites W2530995510 @default.
• W3136304269 cites W2550561592 @default.
• W3136304269 cites W2561961059 @default.
• W3136304269 cites W2593282395 @default.
• W3136304269 cites W2771241464 @default.
• W3136304269 cites W4211152344 @default.
• W3136304269 cites W4239494812 @default.
• W3136304269 doi "https://doi.org/10.1371/journal.pone.0247384" @default.
• W3136304269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7971513" @default.
• W3136304269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33735220" @default.
• W3136304269 hasPublicationYear "2021" @default.
• W3136304269 type Work @default.
• W3136304269 sameAs 3136304269 @default.
• W3136304269 citedByCount "10" @default.
• W3136304269 countsByYear W31363042692021 @default.
• W3136304269 countsByYear W31363042692022 @default.
• W3136304269 countsByYear W31363042692023 @default.
• W3136304269 crossrefType "journal-article" @default.
• W3136304269 hasAuthorship W3136304269A5002202838 @default.
• W3136304269 hasAuthorship W3136304269A5003696666 @default.
• W3136304269 hasAuthorship W3136304269A5019640187 @default.
• W3136304269 hasAuthorship W3136304269A5043049715 @default.
• W3136304269 hasAuthorship W3136304269A5055180890 @default.
• W3136304269 hasAuthorship W3136304269A5058757004 @default.
• W3136304269 hasAuthorship W3136304269A5081400464 @default.
• W3136304269 hasAuthorship W3136304269A5083681911 @default.
• W3136304269 hasAuthorship W3136304269A5084119337 @default.
• W3136304269 hasBestOaLocation W31363042691 @default.
• W3136304269 hasConcept C126322002 @default.
• W3136304269 hasConcept C159654299 @default.
• W3136304269 hasConcept C16005928 @default.
• W3136304269 hasConcept C187212893 @default.
• W3136304269 hasConcept C203014093 @default.
• W3136304269 hasConcept C2777147708 @default.
• W3136304269 hasConcept C2777553296 @default.
• W3136304269 hasConcept C2779159148 @default.
• W3136304269 hasConcept C2779620486 @default.
• W3136304269 hasConcept C2909216522 @default.
• W3136304269 hasConcept C2909371672 @default.
• W3136304269 hasConcept C2993597950 @default.
• W3136304269 hasConcept C42972112 @default.
• W3136304269 hasConcept C71924100 @default.
• W3136304269 hasConceptScore W3136304269C126322002 @default.
• W3136304269 hasConceptScore W3136304269C159654299 @default.
• W3136304269 hasConceptScore W3136304269C16005928 @default.
• W3136304269 hasConceptScore W3136304269C187212893 @default.
• W3136304269 hasConceptScore W3136304269C203014093 @default.
• W3136304269 hasConceptScore W3136304269C2777147708 @default.
• W3136304269 hasConceptScore W3136304269C2777553296 @default.
• W3136304269 hasConceptScore W3136304269C2779159148 @default.
• W3136304269 hasConceptScore W3136304269C2779620486 @default.
• W3136304269 hasConceptScore W3136304269C2909216522 @default.
• W3136304269 hasConceptScore W3136304269C2909371672 @default.
• W3136304269 hasConceptScore W3136304269C2993597950 @default.
• W3136304269 hasConceptScore W3136304269C42972112 @default.

• next